Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicks VapoInhaler is a portable, over-the-counter nasal inhaler designed to provide soothing vapors for temporary relief of nasal congestion. The product is available in both medicated and non-medicated versions. The medicated version contains levmetamfetamine (levomethamphetamine), a sympathomimetic vasoconstrictor that acts as a topical nasal decongestant by constricting blood vessels in the nasal passages, thereby reducing swelling and congestion[1][3][4]. The non-medicated version provides only aromatic relief using menthol, camphor, methyl salicylate, and Siberian fir oil[2][10]. Developed for on-the-go use, it is intended for adults and children 12 years or older. Procter & Gamble developed the original branded product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vicks VapoInhaler.